In re: Lorazepam and Clorazepate Antitrust Litigation
Representation of Blue Cross Blue Shield of Massachusetts, Blue Cross Blue Shield of Minnesota, and Federated Mutual Insurance Company in litigation before the federal District Court in the District of Columbia involving claims of state antitrust law violations regarding competitors' access to raw materials for Lorazepam and Clorazepate. The jury's verdict found that Mylan Laboratories Inc./Mylan Pharmaceuticals Inc., Cambrex Corporation, and Gyma Laboratories violated state antitrust laws and had restrained trade and acted willfully in excluding generic competitors' access. In post-trial motions, the District Court awarded Plaintiffs treble damages, for a total award to all plaintiffs of $76.8 million. The parties are currently awaiting the Court's order on prejudgment interest.
Counsel
Related Links